For virologically suppressed adults with HIV-1. See Full Indication.

Talking to Your Patients About CABENUVA

Which of your patients might be appropriate for CABENUVA?

When determining if CABENUVA is appropriate for your patients, two important areas to consider are:

CLINICAL CONSIDERATIONS1

  • Virologically suppressed adult with HIV-1*
    • On a stable antiretroviral regimen with no history of treatment failure
    • No known or suspected resistance to either cabotegravir or rilpivirine
  • No contraindications
    • No previous hypersensitivity to cabotegravir or rilpivirine
    • No coadministration with drugs where significant decreases in cabotegravir and/or rilpivirine plasma concentrations may occur, which may result in loss of virologic response
  • Consider potential drug-drug interactions
Drug-Drug Interactions

PATIENT CONSIDERATIONS

  • Able to adhere to and agree to required monthly appointments
  • May express interest in
    • Less frequent dosing 
    • An alternative to daily oral therapy

*HIV-1 RNA <50 copies/mL.1

This content is not intended to be a substitute for professional judgement.

Reference:

  1. CABENUVA [package insert]. Research Triangle Park, NC: ViiV Healthcare; 2021.

CBRWCNT210003